Deep Insight — 2026 Investments

1 investments dated 2026 · listed companies and verified rows first · show all

Scalascala-bio.com inSeries A · Mar 2026 · $16M

Scala develops computational protein stability design technology that enables bacterial production of complex human enzymes, applied here to redesign human acetylcholinesterase (AChE) for high-yield, active expression in E. coli.

AI & Machine LearningBiotechDeep Tech

Ravit Netzer(Co-founder & CEO)inAdi Goldenzweig(Co-founder & CTO)inSarel Fleishman(Chief Scientist)in

Co-investorsBullet Ventures IT-Farm Corporation TLV Partners Grove Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.